Guideline for the diagnosis and management of myelofibrosis

Br J Haematol. 2012 Aug;158(4):453-71. doi: 10.1111/j.1365-2141.2012.09179.x. Epub 2012 Jun 1.


The guideline group regarding the diagnosis and management of myelofibrosis was selected to be representative of UK-based medical experts, together with a contribution from a single expert from the USA. MEDLINE and EMBASE were searched systematically for publications in English from 1966 until August 2011 using a variety of key words. The writing group produced the draft guideline, which was subsequently revised by consensus of the members of the General Haematology and Haemato-oncology Task Forces of the British Committee for Standards in Haematology (BCSH). The guideline was then reviewed by a sounding board of UK haematologists, the BCSH and the British Society for Haematology Committee and comments incorporated where appropriate. The criteria used to state levels and grades of evidence are as outlined in the Procedure for Guidelines commissioned by the BCSH; the 'GRADE' system was used to score strength and quality of evidence. The objective of this guideline is to provide healthcare professionals with clear guidance on the investigation and management of primary myelofibrosis, as well as post-polycythaemic myelofibrosis (post-PV MF) and post-thrombocythemic myelofibrosis (post-ET MF) in both adult and paediatric patients.

Publication types

  • Guideline

MeSH terms

  • Anemia / etiology
  • Anemia / therapy
  • Bone Marrow Transplantation / methods
  • Enzyme Inhibitors / therapeutic use
  • Evidence-Based Medicine / methods
  • Hematopoietic Stem Cell Transplantation / methods
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Janus Kinases / antagonists & inhibitors
  • Primary Myelofibrosis / complications
  • Primary Myelofibrosis / diagnosis*
  • Primary Myelofibrosis / genetics
  • Primary Myelofibrosis / therapy*
  • Prognosis
  • Splenectomy


  • Enzyme Inhibitors
  • Immunosuppressive Agents
  • Janus Kinases